Mereo BioPharma (MREO) Share-based Compensation (2023 - 2026)
Mereo BioPharma (MREO) posted quarterly Share-based Compensation of $5.5 million for Q1 2026, up 141.44% year-over-year from $2.3 million in Q1 2025, and up 256.45% quarter-over-quarter from $1.5 million in Q4 2025.
Mereo BioPharma (MREO) Share-based Compensation (2023 - 2026) Analysis & Trends
Mereo BioPharma (MREO) has reported Share-based Compensation for 4 consecutive years, with $5.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation rose 141.44% year-over-year to $5.5 million; the TTM figure through Mar 2026 stood at $5.5 million (down 27.79% YoY), while the FY2025 annual figure was $7.6 million, up 2.81% from the prior year.
- Share-based Compensation grew to $5.5 million in Q1 2026 per MREO's latest filing, from $1.5 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $6.9 million in Q2 2025 and bottomed at $815000.0 in Q4 2023.
- Historically, Share-based Compensation has averaged $2.6 million across 4 years, with a median of $1.7 million in 2024.
- On a YoY basis, Share-based Compensation climbed as much as 230.46% in 2025 and fell as far as 1.85% in 2025.
- Mereo BioPharma's Share-based Compensation stood at $815000.0 in 2023, then jumped by 85.89% to $1.5 million in 2024, then increased by 1.85% to $1.5 million in 2025, then jumped by 256.45% to $5.5 million in 2026.
- Business Quant data shows MREO's Share-based Compensation at $5.5 million in Q1 2026, $1.5 million in Q4 2025, and $5.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Mereo BioPharma | 47.15 Mn | 47.15 Mn | - | 4.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.00 Mn |
| Jun 30, 2026 | 4.00 Mn |
| Mar 31, 2026 | 5.50 Mn |
| Mar 31, 2026 | 5.50 Mn |
| Dec 31, 2025 | 1.54 Mn |
| Dec 31, 2025 | 1.54 Mn |
| Sep 30, 2025 | 5.70 Mn |
| Sep 30, 2025 | 5.70 Mn |
| Jun 30, 2025 | 6.90 Mn |
| Jun 30, 2025 | 6.90 Mn |
| Mar 31, 2025 | 2.28 Mn |
| Mar 31, 2025 | 2.28 Mn |
| Dec 31, 2024 | 1.52 Mn |
| Dec 31, 2024 | 1.52 Mn |
| Sep 30, 2024 | 1.74 Mn |
| Sep 30, 2024 | 1.74 Mn |
| Jun 30, 2024 | 2.09 Mn |
| Jun 30, 2024 | 2.09 Mn |
| Mar 31, 2024 | 2.05 Mn |
| Mar 31, 2024 | 2.05 Mn |